It was revealed that the inhibitory effects of miR-767-5p on glioblastoma cell phenotypes were reversed by overexpression of SUZ12, indicating that the forced upregulation of miR-767-5p may represent a novel therapeutic strategy for glioma patients by targeting SUZ12. This evidence concerns the gene SUZ12 and glioma.